Microsoft, weight loss drug sales, and GSK profits surge
In today's episode, Ian King speaks with Dan Ives - managing director of the brokerage and advisory firm Wedbush Securities - to discuss Microsoft's revenues and AI.
Ian Johnston, global pharmaceutical correspondent at the Financial Times, discuses sales of popular weight loss drug 'Wegvoy', made by Novo Nordisk - as they say their sales almost quadrupled last year.
And, Ian discusses GSK's operating profit of £8.8billion for 2023 with strong selling medicines including its HIV and shingles medication.
Ian Johnston, global pharmaceutical correspondent at the Financial Times, discuses sales of popular weight loss drug 'Wegvoy', made by Novo Nordisk - as they say their sales almost quadrupled last year.
And, Ian discusses GSK's operating profit of £8.8billion for 2023 with strong selling medicines including its HIV and shingles medication.
